Pfizer invests in abuse-resistant painkillers with purchase of King Pharmaceuticals

Published October 19, 2010

Pfizer invests in abuse-resistant painkillers with purchase of King Pharmaceuticals
WASHINGTON – Pfizer’s purchase of King Pharmaceuticals announced Tuesday represents a $ 3.6 billion investment in an emerging class of painkillers that are designed to be less addictive than older pills such as OxyContin.
Read more on Minneapolis-St. Paul Star Tribune